SCHEMBL6797530

SCHEMBL6797530

CC1(C(O)c2ccc(-c3ccc(C(=O)N4CCC(CO)CC4)cc3)cc2)NC(=O)NC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HTR2B P41595 3/20 0.38
ATR Q13535 1/20 0.38
HRH3 Q9Y5N1 2/20 0.38
CRBN Q96SW2 2/20 0.38
POLB P06746 1/20 0.37
PTK2 Q05397 1/20 0.37
PDE5A O76074 1/20 0.36
PDE4A P27815 1/20 0.36
PDE1A P54750 1/20 0.36
PDE1B Q01064 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
PDE7A Q13946 1/20 0.36
PDE1C Q14123 1/20 0.36
PDE3A Q14432 1/20 0.36
PDE7B Q9NP56 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6840968 0.86 HPGD (0.47) SMN1; SMN2ALDH1A1CRBNPOLBPDE5A
SCHEMBL6791869 0.83 HSD11B1 (0.44) SMN1; SMN2ALDH1A1HRH3CRBNPOLB
SCHEMBL6793526 0.75 CA12 (0.40) PDE5APDE1APDE1BPDE4DPDE7A
SCHEMBL6988152 0.74 MCHR1 (0.51) HRH3
SCHEMBL6840876 0.73 NPC1 (0.45) SMN1; SMN2ALDH1A1LMNA
SCHEMBL24628704 0.71 MGLL (0.52) SMN1; SMN2ALDH1A1HTR2BATRLMNA
SCHEMBL8157501 0.71 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1HTR2BPOLBLMNA
SCHEMBL6791153 0.71 MMP2 (0.41) ALDH1A1
SCHEMBL6789361 0.71 MMP2 (0.41) ALDH1A1
SCHEMBL6791227 0.71 MMP2 (0.41) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 PRMT5 740/4885SMN1; SMN2 3091/4885ALDH1A1 294/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 PRMT5 1720/4885SMN1; SMN2 2809/4885ALDH1A1 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.